A Phase 2 interventional study of LUM001 (Maralixibat) in Alagille Syndrome, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 3 sites in United Kingdom. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2021-11-19.
Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Alagille Syndrome · Mirum Pharmaceuticals, Inc..
Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., this one is one of 2 that started in 2013, is one of 6 in phase 2, and was the 2nd registered.
31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.
Browse Alagille Syndrome studies →2 of the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. are open now, in 9 countries. Recruiting first, the newest first:
Mirum Pharmaceuticals, Inc. · Sites in Belgium, France, Germany and 5 more countries
Ages 2 mo+
Mirum Pharmaceuticals, Inc. · Sites in United States
By country, each count listing its studies:
Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 12 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2013.
This study's enrollment of 19 is below the median of 31 across 15 interventional studies indexed under Alagille Syndrome.
Median enrollment 31 across the 7 interventional studies, 47 across the 2 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this extension study is to determine the long-term safety and tolerability of an investigational treatment (LUM001 also known as Maralixibat) in children with ALGS who have completed participation in a core LUM001 treatment protocol. Efficacy will be assessed by evaluating the effect of LUM001 on pruritus, biochemical markers of pruritus, as well as biochemical markers of cholestasis and liver disease.
Participation for an individual patient is expected to be approximately 72 weeks.
Patients who complete 72 weeks of treatment may be eligible to receive treatment for up to 52 weeks during the follow-up treatment period and patients who completed the 124 weeks of treatment may be eligible to enter the additional long-term follow-up period.
LUM001 also known as Maralixibat (MRX) administered orally up to twice each day
Drug: LUM001 (Maralixibat)
Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).
Change From MRX Baseline to Week 48 in Fasting sBA Levels
The primary endpoint of this study was the mean change from MRX baseline to Week 48 in fasting sBA level.
Time frame: MRX baseline to Week 48
Change From MRX Baseline Over Time in Fasting sBA Levels
This secondary efficacy endpoint is the mean change from MRX baseline over time in fasting sBA levels. Results reported here are the long-term results.
Time frame: MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Change From MRX Baseline to Week 48 in Pruritus
This secondary efficacy endpoint is the change from MRX baseline to Week 48 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).
Time frame: MRX baseline to Week 48
Change From MRX Baseline Over Time in Pruritus
This secondary efficacy endpoint is the change from MRX baseline over time in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results.
Time frame: MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Change From MRX Baseline to Week 48 in Clinician Xanthoma Severity Score
This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the participant's lesions interfere or limit his or her activities. Clinician xanthoma severity scores range from 0 to 4, with a xanthoma score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling. Clinician xanthoma severity scores were not assessed in Study LUM001-302 so mean clinician xanthoma severity score at MRX baseline was calculated from the 5 participants who were assigned to placebo in Study LUM001-302, and analysis of change from MRX baseline is not presented.
Time frame: MRX baseline to Week 48
Change From MRX Baseline Over Time in Clinician Xanthoma Severity Score
This secondary efficacy endpoint is the mean change from MRX baseline over time (with Week 252 chosen as the end point, as the last analysis visit with at least 6 participants) in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling. Clinician xanthoma severity scores were not assessed in Study LUM001-302 so mean clinician xanthoma severity score at MRX baseline was calculated from the 5 participants assigned to placebo in Study LUM001-302, and analysis of change from MRX baseline is not presented. Results reported here are the long-term results.
Time frame: MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Secondary: Change From MRX Baseline to Week 48 in Alkaline Phosphatase
This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in ALP.
Time frame: MRX baseline to Week 48
Change From MRX Baseline Over Time in Alkaline Phosphatase
This secondary efficacy endpoint is the mean change from MRX baseline over time in ALP. Results reported here are the long-term results.
Time frame: MRX baseline to end of treatment (maximum exposure was 336 weeks)
Change From MRX Baseline to Week 48 in Alanine Aminotransferase
This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in ALT.
Time frame: MRX baseline to Week 48
Change From MRX Baseline Over Time in Alanine Aminotransferase
This secondary efficacy endpoint is the mean change from MRX baseline over time in ALT levels. Results reported here are the long-term results.
Time frame: MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Change From MRX Baseline to Week 48 in Aspartate Aminotransferase
This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in AST levels.
Time frame: MRX baseline to Week 48
Change From MRX Baseline Over Time in Aspartate Aminotransferase
This secondary efficacy endpoint is the mean change from MRX baseline over time in AST levels. Results reported here are the long-term results.
Time frame: MRX baseline to End of treatment (maximum exposure was 336 weeks)
Change From MRX Baseline to Week 48 in Gamma Glutamyltransferase
This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in GGT.
Time frame: MRX baseline to Week 48
Change From MRX Baseline Over Time in Gamma Glutamyltransferase
This secondary efficacy endpoint is the mean change from MRX baseline over time in GGT. Results reported here are the long-term results.
Time frame: MRX baseline to End of Treatment (maximum exposure was 336 weeks)
Change From MRX Baseline to Week 48 in Total and Direct Bilirubin
This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in total bilirubin and direct bilirubin.
Time frame: MRX baseline to Week 48
Change From MRX Baseline Over Time in Total and Direct Bilirubin
This secondary efficacy endpoint is the mean change from MRX baseline over time in total bilirubin and direct bilirubin. Results reported here are the long-term results.
Time frame: MRX baseline to End of Treatment (maximum exposure was 336 weeks)
| Milestone | LUM001 (Maralixibat) |
|---|---|
| Started | 19 |
| Received mrx 14 ug/kg/day | 6 |
| Received mrx 35 ug/kg/day | 6 |
| Received mrx 70 ug/kg/day | 6 |
| Received mrx 140 ug/kg/day | 11 |
| Received mrx 280 ug/kg/day | 19 |
| Completed | 7 |
| Not completed | 12 |
| Withdrew: Did not consent to 52-week follow- up | 8 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by caregiver | 3 |
| Milestone | LUM001 (Maralixibat) |
|---|---|
| Started | 6 |
| Completed | 6 |
| Not completed | 0 |
| Milestone | LUM001 (Maralixibat) |
|---|---|
| Started | 7 |
| Received mrx 280 ug/kg/day | 7 |
| Received 420 ug/kg/day | 5 |
| Received 560 ug/kg/day | 5 |
| Completed | 6 |
| Not completed | 1 |
| Withdrew: Consent withdrawn by subject | 1 |
The primary endpoint of this study was the mean change from MRX baseline to Week 48 in fasting sBA level.
| μmol/L | Core Study Period: MRX Baseline Values | Core Study Period: Week 48 Values |
|---|---|---|
| Change From MRX Baseline to Week 48 in Fasting sBA Levels | 261.96 ± 206.839 | 128.32 ± 101.742 |
This secondary efficacy endpoint is the mean change from MRX baseline over time in fasting sBA levels. Results reported here are the long-term results.
| μmol/L | Core Study Period: MRX Baseline Value | Week 252 Values |
|---|---|---|
| Change From MRX Baseline Over Time in Fasting sBA Levels | 261.96 ± 206.839 | 118.32 ± 76.140 |
This secondary efficacy endpoint is the change from MRX baseline to Week 48 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).
| scores on a scale | Core Study Period: MRX Baseline Value | Core Study Period: Week 48 Values |
|---|---|---|
| Change From MRX Baseline to Week 48 in Pruritus | 2.435 ± 0.7952 | 1.307 ± 0.6995 |
This secondary efficacy endpoint is the change from MRX baseline over time in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results.
| scores on a scale | Core Study Period: MRX Baseline Value | Week 278 Values |
|---|---|---|
| Change From MRX Baseline Over Time in Pruritus | 2.435 ± 0.7952 | 0.952 ± 0.4302 |
This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the participant's lesions interfere or limit his or her activities. Clinician xanthoma severity scores range from 0 to 4, with a xanthoma score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling. Clinician xanthoma severity scores were not assessed in Study LUM001-302 so mean clinician xanthoma severity score at MRX baseline was calculated from the 5 participants who were assigned to placebo in Study LUM001-302, and analysis of change from MRX baseline is not presented.
| scores on a scale | Core Study Period: MRX Baseline Values | Core Study Period: Week 48 Values |
|---|---|---|
| Change From MRX Baseline to Week 48 in Clinician Xanthoma Severity Score | 0.4 ± 0.55 | 0.2 ± 0.73 |
This secondary efficacy endpoint is the mean change from MRX baseline over time (with Week 252 chosen as the end point, as the last analysis visit with at least 6 participants) in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling. Clinician xanthoma severity scores were not assessed in Study LUM001-302 so mean clinician xanthoma severity score at MRX baseline was calculated from the 5 participants assigned to placebo in Study LUM001-302, and analysis of change from MRX baseline is not presented. Results reported here are the long-term results.
| scores on a scale | Core Study Period: MRX Baseline Value | Week 252 Values |
|---|---|---|
| Change From MRX Baseline Over Time in Clinician Xanthoma Severity Score | 0.4 ± 0.55 | 0.2 ± 0.41 |
This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in ALP.
| U/L | Core Study Period: MRX Baseline Value | Core Study Period: Week 48 Values |
|---|---|---|
| Secondary: Change From MRX Baseline to Week 48 in Alkaline Phosphatase | 601.5 ± 232.54 | 596.2 ± 185.20 |
This secondary efficacy endpoint is the mean change from MRX baseline over time in ALP. Results reported here are the long-term results.
| U/L | Core Study Period: MRX Baseline Value | Week 252 Values |
|---|---|---|
| Change From MRX Baseline Over Time in Alkaline Phosphatase | 601.5 ± 232.54 | 430.5 ± 223.56 |
This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in ALT.
| U/L | Core Study Period: MRX Baseline Value | Core Study Period: Week 48 Values |
|---|---|---|
| Change From MRX Baseline to Week 48 in Alanine Aminotransferase | 130.7 ± 59.12 | 174.5 ± 97.28 |
This secondary efficacy endpoint is the mean change from MRX baseline over time in ALT levels. Results reported here are the long-term results.
| U/L | Core Study Period: MRX Baseline Value | Week 252 Values |
|---|---|---|
| Change From MRX Baseline Over Time in Alanine Aminotransferase | 130.7 ± 59.12 | 175.3 ± 101.17 |
This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in AST levels.
| U/L | Core Study Period: MRX Baseline Values | Core Study Period: Week 48 Values |
|---|---|---|
| Change From MRX Baseline to Week 48 in Aspartate Aminotransferase | 127.6 ± 60.03 | 142.4 ± 78.94 |
This secondary efficacy endpoint is the mean change from MRX baseline over time in AST levels. Results reported here are the long-term results.
| U/L | Core Study Period: MRX Baseline Value | Week 252 Values |
|---|---|---|
| Change From MRX Baseline Over Time in Aspartate Aminotransferase | 127.6 ± 60.03 | 145.0 ± 56.50 |
This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in GGT.
| U/L | Core Study Period: MRX Baseline Value | Core Study Period: Week 48 Values |
|---|---|---|
| Change From MRX Baseline to Week 48 in Gamma Glutamyltransferase | 476.9 ± 376.85 | 440.5 ± 230.60 |
This secondary efficacy endpoint is the mean change from MRX baseline over time in GGT. Results reported here are the long-term results.
| U/L | Core Study Period: MRX Baseline Value | Week 252 Values |
|---|---|---|
| Change From MRX Baseline Over Time in Gamma Glutamyltransferase | 476.9 ± 376.85 | 377.5 ± 163.10 |
This secondary efficacy endpoint is the mean change from MRX baseline to Week 48 in total bilirubin and direct bilirubin.
| mg/dL | Core Study Period: MRX Baseline Value | Core Study Period: Week 48 Values |
|---|---|---|
| Total bilirubin | 4.47 ± 4.837 | 4.25 ± 5.384 |
| Direct bilirubin | 3.80 ± 3.858 | 3.21 ± 3.656 |
This secondary efficacy endpoint is the mean change from MRX baseline over time in total bilirubin and direct bilirubin. Results reported here are the long-term results.
| mg/dL | Core Study Period: MRX Baseline Value | Week 252 Values |
|---|---|---|
| Total bilirubin | 4.47 ± 4.837 | 5.05 ± 6.449 |
| Direct bilirubin | 3.80 ± 3.858 | 3.53 ± 3.727 |
Collected over Treatment-emergent adverse events are AEs with a start date on or after the first dose of study drug and with a start date prior to the last dose of study drug plus 14 days. Maximum exposure was 336 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 14 Microgram Per Kilogram Per Day (mcg/kg/Day) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| 35 Microgram Per Kilogram Per Day (mcg/kg/Day) | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| 70 Microgram Per Kilogram Per Day (mcg/kg/Day) | 0/10 (0%) | 1/10 (10%) | 3/10 (30%) |
| 140 Microgram Per Kilogram Per Day (mcg/kg/Day) | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| 280 Microgram Per Kilogram Per Day (mcg/kg/Day) | 0/19 (0%) | 6/19 (31.6%) | 18/19 (94.7%) |
| 420 Microgram Per Kilogram Per Day (mcg/kg/Day) | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| 560 Microgram Per Kilogram Per Day (mcg/kg/Day) | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| LUM001 MRX Treatment | 0/19 (0%) | 6/19 (31.6%) | 18/19 (94.7%) |
| Event | 14 Microgram Per Kilogram Per Day (mcg/kg/Day) | 35 Microgram Per Kilogram Per Day (mcg/kg/Day) | 70 Microgram Per Kilogram Per Day (mcg/kg/Day) | 140 Microgram Per Kilogram Per Day (mcg/kg/Day) | 280 Microgram Per Kilogram Per Day (mcg/kg/Day) | 420 Microgram Per Kilogram Per Day (mcg/kg/Day) | 560 Microgram Per Kilogram Per Day (mcg/kg/Day) | LUM001 MRX Treatment |
|---|---|---|---|---|---|---|---|---|
| BradycardiaCardiac disorders | 0/6 | 0/10 | 0/10 | 0/13 | 0/19 | 0/5 | 1/5 | 1/19 |
| Right ventricular failureCardiac disorders | 0/6 | 0/10 | 0/10 | 0/13 | 0/19 | 0/5 | 1/5 | 1/19 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/6 | 0/10 | 0/10 | 0/13 | 0/19 | 0/5 | 1/5 | 1/19 |
| Gastrointestinal infectionInfections and infestations | 0/6 | 0/10 | 0/10 | 0/13 | 0/19 | 0/5 | 1/5 | 1/19 |
| Lower respiratory tract infectionInfections and infestations | 0/6 | 0/10 | 0/10 | 0/13 | 0/19 | 0/5 | 1/5 | 1/19 |
| Humerus fractureInjury, poisoning and procedural complications | 0/6 | 0/10 | 0/10 | 0/13 | 0/19 | 0/5 | 1/5 | 1/19 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/6 | 0/10 | 0/10 | 0/13 | 0/19 | 0/5 | 1/5 | 1/19 |
| Pathological fractureMusculoskeletal and connective tissue disorders | 0/6 | 0/10 | 0/10 | 0/13 | 0/19 | 0/5 | 1/5 | 1/19 |
| HypotensionVascular disorders | 0/6 | 0/10 | 0/10 | 0/13 | 0/19 | 0/5 | 1/5 | 1/19 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/6 | 0/10 | 1/10 | 0/13 | 1/19 | 0/5 | 0/5 | 1/19 |
| Event | 14 Microgram Per Kilogram Per Day (mcg/kg/Day) | 35 Microgram Per Kilogram Per Day (mcg/kg/Day) | 70 Microgram Per Kilogram Per Day (mcg/kg/Day) | 140 Microgram Per Kilogram Per Day (mcg/kg/Day) | 280 Microgram Per Kilogram Per Day (mcg/kg/Day) | 420 Microgram Per Kilogram Per Day (mcg/kg/Day) | 560 Microgram Per Kilogram Per Day (mcg/kg/Day) | LUM001 MRX Treatment |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/6 | 0/10 | 0/10 | 2/13 | 7/19 | 0/5 | 4/5 | 8/19 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 0/10 | 1/10 | 2/13 | 7/19 | 0/5 | 3/5 | 11/19 |
| TonsillitisInfections and infestations | 0/6 | 0/10 | 0/10 | 0/13 | 2/19 | 0/5 | 3/5 | 4/19 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/6 | 0/10 | 1/10 | 1/13 | 6/19 | 0/5 | 3/5 | 7/19 |
| Abdominal painGastrointestinal disorders | 1/6 | 2/10 | 1/10 | 4/13 | 10/19 | 0/5 | 1/5 | 11/19 |
| Upper respiratory tract infectionInfections and infestations | 0/6 | 0/10 | 0/10 | 3/13 | 10/19 | 0/5 | 0/5 | 11/19 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/6 | 0/10 | 0/10 | 4/13 | 8/19 | 0/5 | 1/5 | 10/19 |
| PyrexiaGeneral disorders | 0/6 | 0/10 | 0/10 | 2/13 | 6/19 | 0/5 | 1/5 | 8/19 |
| HeadacheNervous system disorders | 0/6 | 0/10 | 0/10 | 0/13 | 4/19 | 0/5 | 2/5 | 6/19 |
| LethargyNervous system disorders | 0/6 | 0/10 | 0/10 | 0/13 | 3/19 | 0/5 | 2/5 | 4/19 |
After a short dose escalation period, participants received MRX 280 ug/kg/day, which consisted of most of their exposure within the study. As such, summaries are presented as a single arm, MRX.
| Age, Customized(Subjects) | Core Study Period |
|---|---|
| <2 years | 3 |
| 2 to 4 years | 6 |
| 5 to 8 years | 5 |
| 9 to 12 years | 2 |
| 13 to 18 years | 3 |
| Sex: Female, Male(Participants) | Core Study Period |
|---|---|
| Female | 9 |
| Male | 10 |
| Race (NIH/OMB)(Participants) | Core Study Period |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 16 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2013 to primary completion in Jun 2020, 77 months.
Results were first posted in Nov 2021, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maralixibat